Anti-Fibrinolytic Drugs - France

France

In France, the revenue in the market of Anti-Fibrinolytic Drugs market is estimated to reach €0.40bn in 2024.
It is expected to exhibit an annual growth rate (CAGR 2024-2029) of 4.14%, leading to a market volume of €0.49bn by 2029.
In terms of global comparison, United States is projected to generate the highest revenue, amounting to €9,141.00m in 2024.
In France, there is an increasing demand for anti-fibrinolytic drugs due to a growing aging population and a rising prevalence of cardiovascular diseases.

Key regions: United Kingdom, Brazil, Europe, France, Canada

Marché

Région

Comparaison de régions

Monnaie

Analyst Opinion

The use of Anti-Fibrinolytic Drugs in France is growing rapidly, driven by the increasing prevalence of bleeding disorders and surgical procedures in the country.

Customer preferences: Patients with bleeding disorders such as hemophilia and von Willebrand disease are the primary users of Anti-Fibrinolytic Drugs in France. These patients require frequent administration of these drugs to prevent excessive bleeding. Additionally, the use of Anti-Fibrinolytic Drugs is also increasing in surgical procedures to reduce bleeding and the need for blood transfusions.

Trends in the market: The Anti-Fibrinolytic Drugs market in France is witnessing significant growth due to the increasing incidence of bleeding disorders and surgeries. The market is also being driven by the availability of new and advanced drugs that are more effective and have fewer side effects. Furthermore, the rising awareness among healthcare professionals and patients about the benefits of these drugs is also contributing to the growth of the market.

Local special circumstances: The French government has implemented several initiatives to improve the healthcare system in the country, which is also driving the growth of the Anti-Fibrinolytic Drugs market. The government has increased healthcare spending and introduced new policies to improve patient access to healthcare services. Additionally, the country has a well-established healthcare infrastructure and a highly skilled workforce, which is also supporting the growth of the market.

Underlying macroeconomic factors: The French economy is one of the largest in Europe and is characterized by a highly developed healthcare sector. The country has a high standard of living and a strong healthcare system, which is driving the growth of the Anti-Fibrinolytic Drugs market. The increasing incidence of bleeding disorders and surgeries in the country is also contributing to the growth of the market. Furthermore, the availability of new and advanced drugs is also expected to drive the growth of the market in the coming years.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.